Tafamidis ATTR Cm denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tafamidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Tafamidis-Attr-Cm as Non-Formulary — and Your Path to Coverage

A non-formulary denial means tafamidis is not included on your specific UHC plan's drug formulary — or is placed on a formulary tier that requires additional authorization or cost-sharing beyond what was expected. This is a coverage-design decision, not a clinical finding. It is entirely separate from whether tafamidis is FDA-approved or medically necessary, and it is appealable through both a formulary exception process and the standard internal appeal pathway.

Formulary exception requests have a meaningful success rate for drugs like tafamidis where (1) no formulary alternative treats the same underlying condition in the same way and (2) the FDA-approved indication is specific and narrow.

## Your Federal Appeal Rights

• Formulary exception request: Before or alongside the internal appeal, submit a formal formulary exception request to UHC. This is distinct from the PA process. UHC is required to have a formulary exception process under ACA rules for non-grandfathered plans.
• Internal appeal (ACA §2719 / ERISA §503): If the exception request is denied, you have the right to a full internal appeal. Request UHC's written rationale and the specific formulary alternatives it believes are therapeutically equivalent.
• External review: After exhausting internal remedies, request IRO review. The IRO will assess whether UHC's denial of the exception was clinically appropriate. Federal law provides approximately four months to initiate external review. Expedited review is available.

## Documentation to Gather

1. Formulary alternative analysis — obtain from UHC the list of formulary alternatives it considers therapeutically equivalent to tafamidis. Your prescriber must then address each one: explain why each alternative is not appropriate for this specific patient's diagnosis and condition. 2. Diagnosis specificity — document that the patient's confirmed diagnosis is ATTR-CM and that tafamidis is the drug approved for this specific condition. Generic "heart failure" agents on the formulary do not treat the underlying TTR protein aggregation. 3. Prescriber medical-necessity and exception letter — the prescriber should state that no formulary alternative addresses the underlying disease mechanism, that substitution would leave the disease process untreated, and that denial of the exception would adversely affect the patient's health. 4. FDA label — attach the current label confirming the approved indication, to support the argument that no formulary alternative shares the same indication. 5. Applicable guideline support — the prescriber should reference the relevant ACC/AHA or applicable guideline organization's recognition of tafamidis as standard of care for ATTR-CM.

## Criteria-Mapping Structure

| UHC Formulary Exception Criterion | Your Documentation | |---|---| | No formulary alternative is clinically appropriate | Prescriber letter addresses each UHC-listed alternative | | Patient's condition is distinct | ATTR-CM diagnosis confirmed; TTR-specific therapy required | | Denial would adversely affect health | Prescriber attestation; disease progression risk documented |

Non-formulary exceptions are frequently granted when the prescriber letter is specific, complete, and addresses every alternative UHC names.